All In Biotech

Drug Trial Radar · NCT00151437

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.

Last checked: Nov 20, 2026Latest source record: Apr 24, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Nov 2004

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.

Conditions

  • Acromegaly

Interventions

  • Pegvisomant treatmentDrug

  • Medical History, demographicsProcedure

  • Sign and symptoms: questionnaireProcedure

  • Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTTProcedure

  • MRIProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient's IGF-1 levels normalize signs and symptoms of acromegaly normalize

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Edmonton, Alberta, Canada

  • Pfizer Investigational Site

    Edmonton, Alberta, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.